Company: DMAC
Filing Date: 2025-03-28
Form Type: DEF 14A
Source: 0001437749-25-009696
Chunk: 4

Company: DiaMedica Therapeutics Inc.
Filing Date: 2025-03-28
Form: DEF 14A
Chunk 4
---
 Investor Relations                                          | ✔     | ✔       |          |         |       | ✔        | ✔       |
| Legal and Compliance/Ethics                                 |       |         |          |         |       | ✔        |         |
| Manufacturing/Operations                                    | ✔     |         |          |         | ✔     | ✔        |         |
| International Experience                                    | ✔     | ✔       | ✔        |         |       | ✔        | ✔       |

<div align='center'>3</div>

EXECUTIVE COMPENSATION BEST PRACTICES

Our compensation practices include many best practices that support our executive compensation objectives and principles and benefit our shareholders.

| What We Do:                                                                             | What We Don’t Do:                                                     |
| ●       Emphasize pay for performance                                                   | ●       No guaranteed salary increases or bonuses                     |
| ●       Structure our executive compensation so a significant portion of pay is at risk | ●       No repricing of stock options unless approved by shareholders |
| ●       Maintain competitive pay packages                                               | ●       No liberal share counting under our equity plan               |
| ●       Structure our executive compensation so a significant portion is paid in equity | ●       No hedging or pledging of DiaMedica securities                |
| ●       Maintain a clawback policy                                                      | ●       No perquisites                                                |

HOW WE PAY

Our executive compensation program consists of the following principal elements which are described under “Executive Compensation.”

| ● | Base salary – a fixed amount, paid in cash and reviewed annually and, if appropriate, adjusted. |

| ● | Short-term incentive – a variable, short-term element that is payable in cash and is based on annual corporate performance objectives and individual performance objectives. |

| ● | Long-term incentive – a variable, long-term element that is provided in stock options. |

2024 EXECUTIVE COMPENSATION ACTIONS

Discussion of our executive compensation program in this proxy statement includes the compensation of the following executive officers required to be named in the Summary Compensation Table under “Executive Compensation” and referred to as our named executive officers or NEOs: (i) Rick Pauls, our Chief Executive Officer (CEO), (ii) Lorianne Masuoka, M.D., our Chief Medical Officer (CMO); and (iii) Scott Kellen, our Chief Financial Officer (CFO). The 2024 compensation actions and incentive plan outcomes based on performance for our NEOs are summarized below:

| Element              | Key 2024 Actions                                                                                                                                                                                                                                                                         |
| Base Salary          | Our